Business Wire

XPENG To Attend IAA Mobility 2023 as EU Deliveries Begin

Share

XPeng Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced the beginning of P7 deliveries in four key European markets and its participation in IAA Mobility 2023, Munich, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830333578/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

European P7 Delivery

Outstanding Smart EVs for Europe

XPENG G9 and P7 were launched in February this year, with excitement around the brand and positive feedback continuing to build up with deliveries beginning.

In June, XPENG G9 broke the charging record at the two-day NAF (Norwegian Automobile Federation) and Motor EV Summer test, also known as El-Prix 2023, reaching a peak charging power of 319 kW. This also represented the test's highest average charging power at 212 kW, allowing drivers to charge up to 100 km of range in just five minutes. G9 and P7 occupied the top two spots in the range test, which measures the real-world deviation rate compared to the stated WLTP range; there was an increase of 13% and 10% for G9(4WD) and P7(4WD), respectively.

As a spacious sports sedan, XPENG P7's cabin provides exceptional comfort, which is surrounded by a sleek exterior epitomizing XPENG's Dynamic Aesthetics design language. Deliveries of P7 recently commenced, with the first batches of vehicles having arrived at XPENG's delivery centers in Lørenskog, Norway; Järfälla, Sweden; Hillerød, Denmark; and Badhoevedorp, The Netherlands.

"We’re delighted that customers who placed orders at the very beginning can finally drive P7 on Europe’s roads,” said Eric Xu, VP of International Markets XPENG. “The feedback has been positive so far, and with our rapidly growing network, we’re very optimistic about our future on the continent.”

Drive With Confidence

As part of the company's dedication to delivering superior customer experiences, XPENG is offering a comprehensive service agreement, which includes an eight-year warranty for the vehicle's battery, as well as a seven-year/160,000 km extended warranty for all orders placed in 2023.

Deliveries of G9 will begin in the coming months as XPENG's network of authorized agencies and partners expands, which will optimize sales, delivery, and servicing processes to create a seamless customer journey.

Learn More About XPENG P7 for Europe

https://www.heyxpeng.com/nl/p7

https://www.heyxpeng.com/dk/p7

https://www.heyxpeng.com/no/p7

https://www.heyxpeng.com/se/p7

XPENG at IAA Mobility 2023

As a technology pioneer in the mobility industry, XPENG will participate in the world's largest mobility event this year, IAA Mobility, on September 4–10, 2023 in Munich. XPENG's agenda is as follows:

  • Pre-IAA XPENG Press Conference
    • H4 Hotel Munich Messe
    • Monday, September 4, 11 am–12 pm
  • IAA Summit Panel: Unleashing the Integrated Smart Ecosystem
    • Blue Stage
    • A discussion on how intelligent and autonomous vehicles are transforming the industry and our overall mobility experience
    • Featuring Co-President and Vice Chairman Brian Gu
    • Tuesday, September 5, 3 pm–3:45 pm
  • Open Space Activation with Product Displays
    • Konigsplatz, Stand KP155
    • Tuesday, September 5 – Sunday, September 10, 10 am–8 pm
  • P7 and G9 Test Drives at Blue Lane*
    • Near Hall C3, Munich Messe
      • Monday, September 4, 8 am–6 pm
      • Tuesday, September 5 – Friday, September 8, 9 am–6 pm
    • Near Konigsplatz
      • Tuesday, September 5 – Saturday, September 9, 10 am–8 pm
      • Sunday, September 10, 10 am–5 pm

*Subject to pre-booking

Follow XPENG at IAA Mobility 2023

Instagram

LinkedIn

Twitter

Facebook

About XPENG

XPENG is a global smart electric vehicle company founded in 2014 in Guangzhou, China, developing clean, intuitive, and creative mobility solutions. With industry-leading R&D facilities, XPENG is bringing vehicles with superior safety, electric efficiency, and on-road performance to markets across the globe. The company is constantly working to advance its core technology offering, including autonomous driving capabilities, SEPA 2.0, and captivating in-car infotainment systems. XPENG has headquarters in Guangzhou and Amsterdam, with additional offices in Beijing, Shanghai, and Silicon Valley.

Visit heyxpeng.com for more information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media Enquiries: pr@xiaopeng.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye